<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03560102</url>
  </required_header>
  <id_info>
    <org_study_id>2017-01282 (BASEC)</org_study_id>
    <secondary_id>2017-MD-0021</secondary_id>
    <nct_id>NCT03560102</nct_id>
  </id_info>
  <brief_title>Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer</brief_title>
  <official_title>Efficacy of Magnetic Resonance-guided High Intensity Focused Ultrasound for the Ablation of Breast Cancer: Correlation Between MRI and Histology. Single-Center, Single-Arm, Non-Randomized Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kantonsspital Winterthur KSW</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kantonsspital Winterthur KSW</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of the study is to evaluate the efficacy of a dedicated Magnetic Resonance guided&#xD;
      High Intensity Focused Ultrasound (MR-HIFU) unit in ablating breast cancer by comparing MR&#xD;
      imaging and pathologic specimen after resection.&#xD;
&#xD;
      Single-center, single-arm, non-randomized trial&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The dedicated MR-HIFU unit has been shown to be safe and feasible to ablate breast tissue.&#xD;
&#xD;
      The planned study should address the possibility to completely ablate breast cancer with the&#xD;
      dedicated breast MR-HIFU unit. The result of the MR-HIFU therapy should be monitored by&#xD;
      imaging (contrast enhanced MRI) as well as with histopathological correlation after surgery.&#xD;
&#xD;
      The patient population would consist of female patients with proven breast cancer scheduled&#xD;
      for surgical lumpectomy or mastectomy.&#xD;
&#xD;
      The idea is to evaluate a minimal invasive method to treat breast cancer as a potential&#xD;
      alternative to surgical resection in the future&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    recruitment difficulties&#xD;
  </why_stopped>
  <start_date type="Actual">January 13, 2020</start_date>
  <completion_date type="Actual">February 5, 2020</completion_date>
  <primary_completion_date type="Actual">February 5, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Accuracy of MRI as Method for Assessment of Quantitative Treatment Success (Correlation With Results of the Histopathological Analysis Performed as Reference Method)</measure>
    <time_frame>Day 14</time_frame>
    <description>Quantitative assessment: Correlation between MRI and histopathology results (volume of necrosis)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of Treatment Efficacy</measure>
    <time_frame>Day 14</time_frame>
    <description>Effective treatment is defined as complete necrosis (100%) of targeted tumor including safety margin (&gt;1mm) (histopathological analysis).&#xD;
Safety margin: measurement of smallest margin on histology and measurement of smallest margin on MRI. Parameter: Percentage of necrosis including safety margin</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Incidence of Adverse Events [Safety and Tolerability of the Treatment]</measure>
    <time_frame>Day 0, 3, 8</time_frame>
    <description>Adverse events, general:&#xD;
Patients will be asked to report information about adverse events at each time point of the study. Information about time of onset, duration, resolution, action to be taken assessment of intensity, relationship with study treatment will be collected.&#xD;
Assessment of additional predefined safety parameters:&#xD;
- Skin changes, assessment in physical examination: presence/absence of redness, burn&#xD;
Palpation breast: lump (mobility of lump related to skin: yes/no)&#xD;
Pain, reported by patient</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">1</enrollment>
  <condition>Breast Cancer, Invasive Ductal</condition>
  <arm_group>
    <arm_group_label>MR-HIFU treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat&amp; resect model</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Philips Sonalleve® MR-HIFU Breast Therapy System</intervention_name>
    <description>The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.</description>
    <arm_group_label>MR-HIFU treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Informed Consent as documented by signature&#xD;
&#xD;
          -  World Health Organization (WHO) performance status≤ 2&#xD;
&#xD;
          -  Body weight ≤ 80 kg&#xD;
&#xD;
          -  Biopsy proven invasive breast cancer with a size of ≤3.0cm (TNM classification: cT1-2&#xD;
             N0-2 MX ).&#xD;
&#xD;
          -  Histological type of tumor: invasive ductal carcinoma (IDC)&#xD;
&#xD;
          -  Patient is scheduled for surgical resection of tumor at study site&#xD;
&#xD;
          -  Tumor location within the reach of the HIFU transducers with the patient in prone&#xD;
             position; distance from skin and pectoral muscle to the tumor ≥ 1.0 cm.&#xD;
&#xD;
          -  Target breast fits in the cup of the dedicated MR-HIFU breast system&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  neoadjuvant systemic therapy&#xD;
&#xD;
          -  prior radiotherapy in target breast&#xD;
&#xD;
          -  contraindications for MRI&#xD;
&#xD;
          -  contraindication for application of gadolinium-based contrast agent&#xD;
&#xD;
          -  contraindication for procedural sedation analgesia&#xD;
&#xD;
          -  macro-calcifications in or around the targeted tumor&#xD;
&#xD;
          -  scar tissue or surgical clips in the direct path of the ultrasound beams&#xD;
&#xD;
          -  Women who are pregnant or breast feeding,&#xD;
&#xD;
          -  Intention to become pregnant during the course of the study,&#xD;
&#xD;
          -  Lack of safe contraception, defined as: Female participants of childbearing potential,&#xD;
             not using and not willing to continue using a medically reliable method of&#xD;
             contraception for the entire study duration, such as oral, injectable, or implantable&#xD;
             contraceptives, or intrauterine contraceptive devices, or who are not using any other&#xD;
             method considered sufficiently reliable by the investigator in individual cases.&#xD;
&#xD;
          -  Known or suspected non-compliance, drug or alcohol abuse,&#xD;
&#xD;
          -  Inability to follow the procedures of the study, e.g. due to language problems,&#xD;
             psychological disorders, dementia, etc. of the participant,&#xD;
&#xD;
          -  Participation in another study with investigational drug/device within the 30 days&#xD;
             preceding and during the present study,&#xD;
&#xD;
          -  Previous enrolment into the current study&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christoph A Binkert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kantonsspital Winterthur KSW</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <zip>CH-8401</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>May 14, 2018</study_first_submitted>
  <study_first_submitted_qc>June 15, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2018</study_first_posted>
  <results_first_submitted>September 23, 2021</results_first_submitted>
  <results_first_submitted_qc>September 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">October 22, 2021</results_first_posted>
  <last_update_submitted>September 23, 2021</last_update_submitted>
  <last_update_submitted_qc>September 23, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>August 31, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/02/NCT03560102/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>First patient enroled: 06JAN2020 Last patient completed: 05FEB2020</recruitment_details>
      <pre_assignment_details>Due to difficulties in recruitment only 2 patients were screened for inclusion and only 1 patient met inclusion criteria and was enrolled in the study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>MR-HIFU Treatment</title>
          <description>Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat&amp; resect model&#xD;
Philips Sonalleve® MR-HIFU Breast Therapy System: The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>MR-HIFU Treatment</title>
          <description>Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat&amp; resect model&#xD;
Philips Sonalleve® MR-HIFU Breast Therapy System: The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="1"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Switzerland</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="163" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="1"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Accuracy of MRI as Method for Assessment of Quantitative Treatment Success (Correlation With Results of the Histopathological Analysis Performed as Reference Method)</title>
        <description>Quantitative assessment: Correlation between MRI and histopathology results (volume of necrosis)</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MR-HIFU Treatment</title>
            <description>Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat&amp; resect model&#xD;
Philips Sonalleve® MR-HIFU Breast Therapy System: The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.</description>
          </group>
        </group_list>
        <measure>
          <title>Accuracy of MRI as Method for Assessment of Quantitative Treatment Success (Correlation With Results of the Histopathological Analysis Performed as Reference Method)</title>
          <description>Quantitative assessment: Correlation between MRI and histopathology results (volume of necrosis)</description>
          <units>percentage of histopathological result</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="168" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Assessment of Treatment Efficacy</title>
        <description>Effective treatment is defined as complete necrosis (100%) of targeted tumor including safety margin (&gt;1mm) (histopathological analysis).&#xD;
Safety margin: measurement of smallest margin on histology and measurement of smallest margin on MRI. Parameter: Percentage of necrosis including safety margin</description>
        <time_frame>Day 14</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MR-HIFU Treatment</title>
            <description>Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat&amp; resect model&#xD;
Philips Sonalleve® MR-HIFU Breast Therapy System: The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.</description>
          </group>
        </group_list>
        <measure>
          <title>Assessment of Treatment Efficacy</title>
          <description>Effective treatment is defined as complete necrosis (100%) of targeted tumor including safety margin (&gt;1mm) (histopathological analysis).&#xD;
Safety margin: measurement of smallest margin on histology and measurement of smallest margin on MRI. Parameter: Percentage of necrosis including safety margin</description>
          <units>percentage of necrosis of targeted tumor</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.9" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Incidence of Adverse Events [Safety and Tolerability of the Treatment]</title>
        <description>Adverse events, general:&#xD;
Patients will be asked to report information about adverse events at each time point of the study. Information about time of onset, duration, resolution, action to be taken assessment of intensity, relationship with study treatment will be collected.&#xD;
Assessment of additional predefined safety parameters:&#xD;
- Skin changes, assessment in physical examination: presence/absence of redness, burn&#xD;
Palpation breast: lump (mobility of lump related to skin: yes/no)&#xD;
Pain, reported by patient</description>
        <time_frame>Day 0, 3, 8</time_frame>
        <group_list>
          <group group_id="O1">
            <title>MR-HIFU Treatment</title>
            <description>Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat&amp; resect model&#xD;
Philips Sonalleve® MR-HIFU Breast Therapy System: The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Adverse Events [Safety and Tolerability of the Treatment]</title>
          <description>Adverse events, general:&#xD;
Patients will be asked to report information about adverse events at each time point of the study. Information about time of onset, duration, resolution, action to be taken assessment of intensity, relationship with study treatment will be collected.&#xD;
Assessment of additional predefined safety parameters:&#xD;
- Skin changes, assessment in physical examination: presence/absence of redness, burn&#xD;
Palpation breast: lump (mobility of lump related to skin: yes/no)&#xD;
Pain, reported by patient</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="1"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Follow-up: Day 2, Day 8 (End of study)</time_frame>
      <group_list>
        <group group_id="E1">
          <title>MR-HIFU Treatment</title>
          <description>Patients with breast cancer and scheduled surgical resection (lumpectomy or mastectomy) will be treated with Philips Sonalleve® MR-HIFU Breast Therapy System prior to surgery in a treat&amp; resect model&#xD;
Philips Sonalleve® MR-HIFU Breast Therapy System: The breast tumor lesion of qualified study patients will be treated with MR-HIFU under procedural sedation with Propofol and Ketamine.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="1"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Christoph A Binkert (Sponsor-Investigator)</name_or_title>
      <organization>Kantonsspital Winterthur</organization>
      <phone>+41 52 266 2602</phone>
      <email>christoph.binkert@ksw.ch</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

